Opus Genetics, Inc. (IRD) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $1.88M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $1.88M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $1.88M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 105.95M USD | Liabilities |
| Borrowing debt | (m) | Long-term Debt, Excluding Current Maturities |
| Amounts owed to suppliers | 1.88M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | Deferred Revenue · Contract with Customer, Liability, Current · Deferred Revenue, Noncurrent |
| Deferred revenue due within one year | (m) | Contract with Customer, Liability, Current |
| Deferred revenue due after one year | (m) | Deferred Revenue, Noncurrent · Deferred Revenue · Contract with Customer, Liability, Current |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | (m) | |
| Deferred revenue included in other noncurrent obligations | (m) | Deferred Revenue · Contract with Customer, Liability, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Obligation categories | (m) |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.88M | (m) | (m) | (m) | $105.95M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $4.42M | (m) | (m) | (m) | $87.89M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $3.29M | (m) | (m) | (m) | $34.90M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $2.40M | (m) | (m) | (m) | $30.16M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $1.47M | (m) | (m) | (m) | $21.19M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $2.43M | (m) | (m) | (m) | $24.25M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $3.15M | (m) | (m) | (m) | $11.29M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $844.00K | (m) | (m) | (m) | $6.09M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $634.00K | (m) | (m) | (m) | $4.20M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $2.06M | (m) | (m) | (m) | $5.79M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $2.15M | $0.00 | (m) | (m) | $4.04M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $1.89M | (m) | (m) | (m) | $3.91M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $2.32M | (m) | (m) | (m) | $5.76M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $2.22M | (m) | (m) | (m) | $4.15M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $1.07M | $636.00K | (m) | (m) | $2.75M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $1.47M | (m) | (m) | (m) | $2.69M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $1.89M | (m) | (m) | (m) | $3.30M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $1.58M | (m) | (m) | (m) | $3.21M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $1.58M | (m) | (m) | (m) | $3.85M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $1.43M | (m) | (m) | (m) | $2.64M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $1.50M | (m) | (m) | (m) | $2.70M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $1.42M | (m) | (m) | (m) | $2.31M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $1.21M | (m) | (m) | (m) | $31.15M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $3.12M | (m) | $650.00K | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $3.25M | (m) | $650.00K | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $2.11M | (m) | $600.00K | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $3.01M | (m) | $1.50M | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | $3.23M | (m) | $1.50M | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $4.05M | (m) | $1.50M | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $3.49M | (m) | $150.00K | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $5.48M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | $7.46M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | $6.81M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | $7.58M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | $11.52M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | $9.47M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | $12.19M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | $18.45M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | $3.99M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | $5.50M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | $4.72M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | $8.35M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | $6.03M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | $5.37M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | $5.94M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | $7.10M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | $6.95M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | $7.86M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | $8.94M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | $13.09M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | $6.93M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | $6.22M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | $5.57M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | $4.98M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | $5.39M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | $3.24M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | $2.09M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | $3.05M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | $2.98M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | $8.52M | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | $10.40M | (m) | (m) | $862.50K | (m) | $0.00 |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | $5.82M | (m) | (m) | $900.00K | (m) | $0.00 |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |